The ability of cancer immunotherapy to harness the body's own immune system to target and kill tumor cells has proven to be clinically formidable. To date, immune checkpoint blockade therapies have been demonstrated to be of substantial clinical benefit in cancer patients. V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is a novel inhibitory immune-checkpoint molecule that suppresses CD4+ and CD8+ T cell activation when expressed on antigen-presenting cells and represents another compensatory inhibitory pathway in tumors. Creative Biolabs offers the best guarantee in the industry of genetically engineering models and has successfully launched an optimized Magic™ “humanized” animal platform to offer specialty humanized VISTA immune checkpoint knock-in mice for our clients all over the world.
VISTA Immune Checkpoint Pathway
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA, gene name Vsir), a type I transmembrane protein, is an inhibitory B7 family immune-checkpoint molecule. Similar with other T cell co-inhibitory receptors such as CTLA-4, PD-1, TIM3, and LAG3, these immune-checkpoint proteins play crucial roles in maintaining peripheral tolerance and controlling immune responses against self and infectious agents, or cancer. VISTA shares homology to PD-L1, and like PD-L1, potently suppresses T-cell activation.
VISTA is predominantly expressed in hematopoietic tissues or in tissues that contain significant numbers of infiltrating leukocytes, such as CD11b+ myeloid dendritic cells (DCs), naïve CD4+ and CD8+ T cells, and Foxp3+ CD4+ regulatory T cells. And this suggests the importance of VISTA for immune-related functions. Like CTLA-4 and PD-1, VISTA controls peripheral tolerance and anti-tumor immunity. VISTA expressed on APCs acts as a ligand to restrain the proliferation and cytokine production of both CD4+ and CD8+ T cells. VISTA also suppresses T cell activation in a T-cell autonomous manner when expressed on CD4+ T cells.
Development of Humanized VISTA Immune Checkpoint Knock-In Mice
It has been reported that treatment with VISTA-blocking monoclonal antibody (mAb) enhanced T responses and anti-tumor immunity. Furthermore, it is also demonstrated that VISTA and another B7 family immune-checkpoint PD-1 play non-redundant roles in controlling T cell responses. VISTA is regarded as a promising new target for cancer immunotherapy, either as a single target or in combination with other immunotherapeutic strategies. With advanced technology and years of experience, Creative Biolabs has successfully established an array of well-characterized Magic™ “humanized” animal models, which can provide you with humanized immune checkpoint knock-in mouse models including humanized VISTA knock-in mouse. Our scientists are willing to assist you in your studies of anti-tumor immunotherapies. Please feel free to contact us for more detailed information.
Creative Biolabs also offers other various Humanized Mouse Models you may be interested in:
For Research Use Only.
